IDYA News and Press, IDEAYA Biosciences Inc. From 10/27/25

IDEAYA Biosciences to Participate in Upcoming November 2025 Investor Relations Events PR Newswire SOUTH SAN FRANCISCO, Calif. , Oct. 27, 2025 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and dev...

2025-10-21 09:15:09 ET Goldman Sachs analyst issues NEUTRAL recommendation for IDYA on October 21, 2025 11:29AM ET. The previous analyst recommendation was Neutral. IDYA was trading at $30.51 at issue of the analyst recommendation. The overall analyst consensus : BUY. ...

IDEAYA Biosciences Announces Positive Phase 2 Data for Darovasertib in the Neoadjuvant Setting of Primary Uveal Melanoma in a Proffered Paper Oral Presentation at ESMO 2025 PR Newswire 83% (78/94) of patients demonstrated ocular tumor shrinkage, with 54% (51/94) achieving ≥2...

IDEAYA Biosciences Reports Positive Median Overall Survival Data from Phase 2 Trial of the Darovasertib and Crizotinib Combination in First-line Metastatic Uveal Melanoma at the 2025 Society for Melanoma Research Congress PR Newswire Combination demonstrated median overall survival...

2025-10-15 09:11:03 ET https://markets-headlines.com/wp-content/uploads/2025/10/Next-Generation-Targeted-Therapies-Reshape-Precision-Oncology-Landscape.mp4 USA News Group News Commentary Issued on behalf...

2025-09-18 14:28:41 ET More on Immunocore Immunocore Holdings Plc (IMCR) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript Immunocore Holdings plc 2025 Q2 - Results - Earnings Call Presentation Immunocore Holdings plc (IMCR) Q2 2025 Earni...

2025-09-08 18:41:22 ET IDEAYA Biosciences, Inc. (IDYA) 10-Year Anniversary R&D Day Conference Call Company Participants Yujiro Hata - Founder, President, CEO & Director Arun D. Singh - Director of Ophthalmic Oncology, Cleveland Clinic Darrin M. Beaupre - Ch...

2025-09-08 16:30:23 ET The last time I wrote about IDEAYA Biosciences ( IDYA ), it was with respect to a Seeking Alpha article entitled " Ideaya Biosciences: Value Beyond Darovasertib With ADC Program IDE849 ." With respect to this article, I noted that the company's opp...

Breakthrough Therapy Designations Surge as $50B Cancer Drug Partnerships Reshape Market Canada NewsWire USA News Group News Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC , Sept. 8, 2025 /CNW/ -- USA ...

IDEAYA Biosciences Announces Positive Data From Phase 1/2 Combination Trial of IDE397, a potential first-in-class MAT2A inhibitor, and Trodelvy® in MTAP-Deletion Urothelial Cancer PR Newswire Overall response rate ( ORR ) of 57% (4/7; 3cPR+1uPR) in patients treated wi...